– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4…
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular…
THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today…
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's…
Xtalks is proud to serve as an official Media Partner for the 9th Operational Excellence in Clinical Trials (OECT) Summit,…
LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market…
Expands international footprint with entry into Asia-Pacific, building on recent CE Mark and UK approvalsATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE)…
Analysis shows Omada members maintained weight, with minimal (0.8%) average weight change, one year after discontinuing GLP-1s for weight loss,1…
- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody- Safety profile observed in first four dose cohorts supports…
Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European UnionMARLBOROUGH, Mass. and YOKNEAM ILLIT,…